InhaleRx Limited (IRX.AX)
AUD 0.03
(0.0%)
AUD 0.03
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 911.41 Thousand AUD | 156.51% |
| 2022 | 355.31 Thousand AUD | 40.25% |
| 2021 | 253.34 Thousand AUD | -56.33% |
| 2020 | 580.1 Thousand AUD | 104.53% |
| 2019 | 283.62 Thousand AUD | -30.54% |
| 2018 | 408.32 Thousand AUD | -29.54% |
| 2017 | 579.51 Thousand AUD | -53.54% |
| 2016 | 1.24 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 633.74 Thousand AUD | -30.47% |
| 2024 Q2 | 633.74 Thousand AUD | 0.0% |
| 2023 FY | 911.41 Thousand AUD | 156.51% |
| 2023 Q1 | 468.1 Thousand AUD | 41.81% |
| 2023 Q2 | 468.1 Thousand AUD | 0.0% |
| 2023 Q3 | 911.12 Thousand AUD | 94.64% |
| 2023 Q4 | 911.41 Thousand AUD | 0.03% |
| 2022 Q4 | 330.09 Thousand AUD | -7.1% |
| 2022 Q2 | 336.46 Thousand AUD | 0.0% |
| 2022 FY | 355.31 Thousand AUD | 40.25% |
| 2022 Q1 | 336.46 Thousand AUD | 32.81% |
| 2022 Q3 | 355.31 Thousand AUD | 5.6% |
| 2021 Q1 | 508.17 Thousand AUD | 35.24% |
| 2021 FY | 253.34 Thousand AUD | -56.33% |
| 2021 Q3 | 253.34 Thousand AUD | -50.15% |
| 2021 Q2 | 508.17 Thousand AUD | 0.0% |
| 2021 Q4 | 253.34 Thousand AUD | 0.0% |
| 2020 Q3 | 580.1 Thousand AUD | 149.42% |
| 2020 FY | 580.1 Thousand AUD | 104.53% |
| 2020 Q4 | 375.76 Thousand AUD | -35.22% |
| 2020 Q2 | 232.58 Thousand AUD | 0.0% |
| 2020 Q1 | 232.58 Thousand AUD | -18.0% |
| 2019 Q2 | 345.8 Thousand AUD | 0.0% |
| 2019 Q1 | 345.8 Thousand AUD | -15.31% |
| 2019 FY | 283.62 Thousand AUD | -30.54% |
| 2019 Q4 | 283.62 Thousand AUD | 0.0% |
| 2019 Q3 | 283.62 Thousand AUD | -17.98% |
| 2018 Q3 | 408.32 Thousand AUD | -26.06% |
| 2018 Q1 | 552.27 Thousand AUD | -4.7% |
| 2018 FY | 408.32 Thousand AUD | -29.54% |
| 2018 Q4 | 408.32 Thousand AUD | 0.0% |
| 2018 Q2 | 552.27 Thousand AUD | 0.0% |
| 2017 Q1 | 345.4 Thousand AUD | 0.0% |
| 2017 Q4 | 579.51 Thousand AUD | 4.66% |
| 2017 FY | 579.51 Thousand AUD | -53.54% |
| 2017 Q2 | 345.4 Thousand AUD | 0.0% |
| 2017 Q3 | 553.72 Thousand AUD | 60.31% |
| 2016 Q2 | 81.72 Thousand AUD | 0.0% |
| 2016 FY | 1.24 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| 4DMedical Limited | 49.08 Million AUD | 98.143% |
| Adherium Limited | 3.4 Million AUD | 73.247% |
| Aroa Biosurgery Limited | 14.77 Million AUD | 93.833% |
| Atomo Diagnostics Limited | 1.29 Million AUD | 29.588% |
| Anteris Technologies Ltd | 17.03 Million AUD | 94.651% |
| Control Bionics Limited | 2.75 Million AUD | 66.973% |
| CardieX Limited | 8.56 Million AUD | 89.356% |
| Compumedics Limited | 22.14 Million AUD | 95.885% |
| Cochlear Limited | 904.6 Million AUD | 99.899% |
| CleanSpace Holdings Limited | 6.94 Million AUD | 86.886% |
| Cyclopharm Limited | 13.65 Million AUD | 93.325% |
| EMVision Medical Devices Ltd | 5.45 Million AUD | 83.294% |
| Nova Eye Medical Limited | 8.55 Million AUD | 89.343% |
| HeraMED Limited | 1.5 Million AUD | 39.479% |
| Imricor Medical Systems, Inc. | 25 Million AUD | 96.355% |
| ImpediMed Limited | 6.24 Million AUD | 85.401% |
| LBT Innovations Limited | 5.5 Million AUD | 83.453% |
| Micro-X Limited | 12.63 Million AUD | 92.786% |
| Neurotech International Limited | 314.69 Thousand AUD | -189.614% |
| OncoSil Medical Limited | 1.98 Million AUD | 54.015% |
| PolyNovo Limited | 37.04 Million AUD | 97.54% |
| Respiri Limited | 3.55 Million AUD | 74.355% |
| SomnoMed Limited | 24.78 Million AUD | 96.322% |
| Universal Biosensors, Inc. | 10.61 Million AUD | 91.412% |
| Uscom Limited | 2.07 Million AUD | 56.046% |
| Visioneering Technologies, Inc. | 2.76 Million AUD | 67.06% |